ERK1/2-targeted Cancer therapies: Recent advances, potential drug resistance, and applicability analysis of emerging technologies
Authors:
- 19 March 2026
- journal article
- review article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 175, 109775
Abstract
No abstract availableKeywords
Funding Information
- Shenzhen Science and Technology Innovation Program
- Shenzhen University
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20240813161112017)
This publication has 83 references indexed in Scilit:
- Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapyActa Pharmaceutica Sinica B, 2022
- The therapeutic effects of tumor treating fields on cancer and noncancerous cellsArabian Journal of Chemistry, 2021
- Discovery of 3( S )-thiomethyl pyrrolidine ERK inhibitors for oncologyBioorganic & Medicinal Chemistry Letters, 2018
- Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancerJournal of Cell Communication and Signaling, 2018
- Negative feedback regulation of the ERK1/2 MAPK pathwayCellular and Molecular Life Sciences, 2016
- ERK1/2 can feedback-regulate cellular MEK1/2 levelsCellular Signalling, 2015
- Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway OncogenesCancer Cell, 2015
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant TumorsCancer Cell, 2014
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E MelanomasCancer Cell, 2012
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010